注射用丹参冻干粉针与阿司匹林抗血栓相互作用研究

Study on the interaction of injection salvia miltiorrhiza dried powder and aspirin in antithrombotic function

目的建立心肌梗死大鼠模型，探讨丹参与阿司匹林联合应用在抗血栓方面的相互作用。方法采用结扎大鼠冠状动脉左主干建立急性心肌梗死大鼠模型。将大鼠随机分为模型组、阿司匹林组、丹参组、联合用药组，每组8只。丹参组经尾静脉注射丹参冻干粉针17mg＆g；阿司匹林组灌胃阿司匹林10mg／kg;联合用药组灌胃阿司匹林10mg／kg，尾静脉注射丹参冻干粉针17mg/kg;模型组灌胃等体积生理盐水，并尾静脉注射等体积生理盐水。1次／d，连续给药10d。末次给药后，检测各组大鼠血小板凝集率、血栓素B2（thromboxaneB2，TXB2）、6-酮-前列腺素（6-ketone prostaglandin，6-Keto-PGF1α）、凝血酶原时间、血管性血友病因子（von willebrand factor,vWF）水平。结果与模型组比较，阿司匹林组、丹参组、联合用药组大鼠血小板聚集率最大值[（32．55±9．57）％、（32．16±10．76）％、（19．74±6．70）％比（58．75±4．81）％]、血浆TXB江（70．58±9．31）ng／ml、（73．10±11．33）ng／ml、（49．25±5．33）ng／ml比（107．86±17．45）ng／m1]降低（P〈0．01），且联合用药组大鼠血小板聚集率最大值、TXB2较阿司匹林组、丹参组均降低（P〈0．01）；阿司匹林组、联合用药组6-Keto-PGF1α含量[（67．64±7．12）ng／ml、（81．72±10．72）ng／ml比（57．80±11．19）ng／m1]升高（P〈O．05），凝血酶原时间[（13．1l±0．67）S、（15．85±0．25）S比（10．77±0．46）s]延长护〈0．05），vWF[（5l_3l±4．12）ng／ml、（47．72±10．32）ng／ml比（128．81±11．14）ng／m1]降低（P〈0．05），且联合用药组6-Keto-PGFk含量较阿司匹林组、丹参组升高（P〈O．05），凝血酶原时间较阿司匹林组、丹参组均延长（P〈O．05），vWF较丹参组降低（P〈O．05）。结论丹参与阿司匹林联合用药对抗血小板聚集功能及抗凝功能存在增效作用。

Objective To investigate the antithrombotic function of traditional medicine salvia and aspirin in the myocardial infarction rats. Methods The myocardial infarction animal model was established by ligating left anterior descending coronary artery. The rats were randomly divided into the model group, the aspirin group, the salvia miltiorrhiza group, and the combination therapy group, with 8 rats in each group. The salvia miltiorrhiza group was injected with Danshen freeze-dried powder 17 mg/kg via tail vein injection, aspirin group was given aspirin 10 mg/kg, the combination group was given aspirin l0 mg/kg with the tail vein injected with Danshen freeze-dried powder 17 mg/kg, and the model group was given an equal volume of normal saline with an equal volume of saline injected into the tail vein. Continuous administration last 10 days, once daily. The blood coagulation, platelet aggregation, thromboxane B2, 6-Keto-Flα, and von Willebrand factor were detected and compared. Results Compared with the model group, the maximum platelet aggregation rate（32.55% 9.57 %, 32.16% ± 10.76%, 19.74% ± 6.70% vs. 58.75% ± 4.81%） in the rats of the aspirin group, the salvia group and the combined treatment group significantly decreased, and the contents of TXB2 （70.58 ± 9.31 ng/ml, 73.10± 11.33 ng/ml, 49.25 ± 5.33 ng/ml vs. 107.86 ± 17.45 ng/ml） decreased （P〈0.01）. The maximum platelet aggregation rate and contents of TXB2 in the combination group were lower than those in the aspirin group and the salvia group （P〈0.01）. Compared with the model group, the 6-Keto-PGF1α content （67.64 ± 7.12 ng/ml, 81.72 ± 10.72 ng/ml vs. 57.80± 11.19 ng/ml） of the aspirin group and the combined treatment groupwas increased （P〈0.05）, prothrombin time （13.11 ± 0.67 s, 15.85 ± 0.25 s vs. 10.77 ± 0.46 s） prolonged （P〈0.05）, vWF （51.31± 4.12 ng/ml, 47.72 ± 10.32 ng/ml vs. 128.81 ± 11.14 ng/ml） decreased （P〈0.05）. The contents of 6-Keto-PGFm of the combined treatment group was increased compared with aspirin group and salvia group （P〈0.05）, prothrombin time decreased than aspirin group （P〈0.05） and Salvia group and vWF decreased than Salvia group （P〈0.05）. Conclusions The salvia miltiorrhiza and aspirin combination therapy has synergistic effect on anti-platelet aggregation and anticoagulant effect. The salvia miltiorrhiza and aspirin combination therapy showed small bleeding risk.